Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 4/20 | 0.64 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11888589 | 0.78 | STAT5B (1.00) | STAT5BKMT2AALDH1A1MEN1 | |
| SCHEMBL20041808 | 0.78 | STAT5B (0.64) | STAT5BKMT2AHDAC1HDAC6MEN1 | |
| SCHEMBL22096025 | 0.75 | STAT5B (0.67) | STAT5BCYP19A1 | |
| SCHEMBL14399057 | 0.69 | STAT5B (0.52) | STAT5BKMT2A | |
| SCHEMBL20041811 | 0.69 | STAT5B (0.52) | STAT5B | |
| SCHEMBL22096008 | 0.66 | ALDH1A1 (0.67) | STAT5BEGLN3KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL31248110 | 0.66 | HDAC1 (0.43) | EGLN3KMT2AALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL22096016 | 0.65 | STAT5B (0.81) | STAT5BALDH1A1HPGDSMN1; SMN2HDAC6 | |
| SCHEMBL22096015 | 0.64 | STAT5B (1.00) | STAT5BALDH1A1HPGD | |
| SCHEMBL22096028 | 0.63 | STAT5B (0.80) | STAT5BKMT2AALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3523297-B1 | NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER | UNIV BERLIN FREIE (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FREIE UNIVERSITAET BERLIN (DE) | 2020-06-16 | — | — | US | disclosed |
| WO-2018065536-A1 | NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER | FREIE UNIVERSITÄT BERLIN (DE) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FLT3, MCL1, MYD88 | STAT5B 59/4885EGLN3 1237/4885KMT2A 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.